Sequenom Introduces the MassARRAY Analyzer 4 System. Next-Generation Proprietary Platform Makes High-Performance Mass Spectrometry Available to Broad Market

SAN DIEGOApril 19 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq:SQNM - News) today announced the launch of its next-generation mass spectrometry system – the MassARRAY® Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance. With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases.

But equipment is not something, which will make this company's sales explode. We are all waiting for the Down's Syndrome test announcement.


Anonymous said...

Let's hope that the Down's Syndrome test will be announced soon!

Post a Comment